Paul W. Noble
- Efficacy of BIBF 1120 in patients with IPF is dose-dependent: Results from the TOMORROW trialBy Ulrich Costabel, Luca Richeldi, Moises Selman, Dong Soon Kim, Kevin K. Brown, Kevin R. Flaherty, Paul W. Noble, Ganesh Raghu, Michèle Brun, Abhya Gupta, Matthias Klueglich, Nolwenn Juhel and Roland M. du BoisUlrich Costabel1Ruhrlandklinik and Medical Faculty, University of Duisburg-Essen, Essen, GermanyLuca Richeldi2Center for Rare Lung Disease, University of Modena and Reggio Emilia, Modena, ItalyMoises Selman3Instituto Nacional de Enfermedades Respiratorias, “Ismael Cosio Villegas”, México, MexicoDong Soon Kim4Division of Pulmonary and Critical Care Medicine, Asan Medical Center, Seoul, KoreaKevin K. Brown5Division of Pulmonary Sciences and Critical Care Medicine, Department of Medicine, National Jewish Health, Denver, United StatesKevin R. Flaherty6Department of Internal Medicine, Pulmonary and Critical Care Division, University of Michigan, Ann Arbor, United StatesPaul W. Noble7Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, Duke University Medical Center, Durham, United StatesGanesh Raghu8Division of Pulmonary and Critical Care Medicine, University of Washington, Seattle, United StatesMichèle Brun9Boehringer Ingelheim France S.A.S., Boehringer Ingelheim, Reims, FranceAbhya Gupta10Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim, Biberach, GermanyMatthias Klueglich10Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim, Biberach, GermanyNolwenn Juhel9Boehringer Ingelheim France S.A.S., Boehringer Ingelheim, Reims, FranceRoland M. du Bois11National Heart & Lung Institute, Imperial College, London, United Kingdom
- Effect of baseline FVC on preservation of lung function with BIBF 1120: Results from the TOMORROW trialBy Luca Richeldi, Ulrich Costabel, Moises Selman, Dong Soon Kim, Kevin R. Flaherty, Paul W. Noble, Ganesh Raghu, Arata Azuma, Michèle Brun, Abhya Gupta, Matthias Klueglich, Nolwenn Juhel and Roland M. du BoisLuca Richeldi1Center for Rare Luna Disease, University of Modena and Reggio Emilia, Modena, ItalyUlrich Costabel2Ruhrlandklinik and Medical Faculty, University of Duisburg-Essen, Essen, GermanyMoises Selman3Instituto Nacional de Enfermedades Respiratorias, “Ismael Cosio Villegas”, Mèxico, MexicoDong Soon Kim4Division of Pulmonary and Critical Care Medicine, Asan Medical Center, University of Ulsan, Seoul, KoreaKevin R. Flaherty5Department of Internal Medicine, Pulmonary and Critical Care Division, University of Michigan, Ann Arbor, United StatesPaul W. Noble6Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, Duke University Medical Center, Durham, United StatesGanesh Raghu7Division of Pulmonary and Critical Care Medicine, University of Washington, Seattle, United StatesArata Azuma8Division of Respiratory Medicine, Infection and Oncology, Nippon Medical School, Tokyo, JapanMichèle Brun9Boehringer Ingelheim France S.A.S., Boehringer Ingelheim, Reims, FranceAbhya Gupta10Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim, Biberach, GermanyMatthias Klueglich10Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim, Biberach, GermanyNolwenn Juhel9Boehringer Ingelheim France S.A.S., Boehringer Ingelheim, Reims, FranceRoland M. du Bois11National Heart & Lung Institute, Imperial College, London, United Kingdom
- 6-minute walk distance is an independent predictor of mortality in patients with idiopathic pulmonary fibrosisBy Roland M. du Bois, Carlo Albera, Williamson Z. Bradford, Ulrich Costabel, Jonathan A. Leff, Paul W. Noble, Steven A. Sahn, Dominique Valeyre, Derek Weycker and Talmadge E. KingRoland M. du Bois1Imperial College London, London, UKCarlo Albera2University of Turin, Turin, ItalyWilliamson Z. Bradford3InterMune Inc., Brisbane, CA, USAUlrich Costabel4Ruhrlandklinik, Essen, GermanyJonathan A. Leff3InterMune Inc., Brisbane, CA, USAPaul W. Noble5Cedars Sinai Medical Center, Los Angeles, CA, USASteven A. Sahn6Medical University of South Carolina, Charleston, SC, USADominique Valeyre7Assistance Publique-Hôpitaux, Paris, FranceDerek Weycker8Policy Analysis Inc., Brookline, MA, USATalmadge E. King Jr9University of California, San Francisco, CA, USA
- 6-minute walk test distance is an independent predictor of mortality in patients with idiopathic pulmonary fibrosisBy Roland M du Bois, Carlo Albera, Williamson Z. Bradford, Ulrich Costabel, Jonathan A. Leff, Paul W. Noble, Steven A. Sahn, Dominique Valeyre, Derek Weycker and Talmadge E. KingArticle | Published in 2013 in European Respiratory JournalRoland M du Bois*Imperial College, London, UKCarlo Albera#University of Turin, ItalyWilliamson Z. Bradford¶InterMune Inc, Brisbane, CAUlrich Costabel+Ruhrlandklinik, Essen, GermanyJonathan A. Leff¶InterMune Inc, Brisbane, CAPaul W. Noble§Cedars Sinai Medical Center, Los Angeles, CASteven A. SahnfMedical University of South Carolina, Charleston, SCDominique Valeyre**Assistance Publique-Hôpitaux, Paris, FranceDerek Weycker##Policy Analysis Inc., Brookline, MATalmadge E. King Jr¶¶University of California, San Francisco, CA
- Late-breaking abstract: Pirfenidone (PFD) effect on morbidity and mortality in patients with idiopathic pulmonary fibrosis (IPF)By Paul W. Noble, Carlo Albera, Williamson Z. Bradford, Ulrich Costabel, Roland M. du Bois, Robert S. Fishman, Ian Glaspole, Marilyn K. Glassberg, Lisa Lancaster, David Lederer, Jonathan A. Leff, Steven D. Nathan, Carlos A. Pereira, Jeffrey J. Swigris, Dominique Valeyre and Talmadge E. KingPaul W. Noble1Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA,Carlo Albera2Department of Clinical and Biological Sciences, University of Turin, Turin, ItalyWilliamson Z. Bradford3Research & Development, InterMune Inc., Brisbane, CA,Ulrich Costabel4Department of Pneumology, Ruhrlandklinik, Essen, GermanyRoland M. du Bois5Respiratory Medicine, Imperial College, London, United KingdomRobert S. Fishman3Research & Development, InterMune Inc., Brisbane, CA,Ian Glaspole6Interstitial Lung Disease, Alfred Hospital, Melbourne, AustraliaMarilyn K. Glassberg7Pulmonology, University of Miami Miller School of Medicine, Miami, FL,Lisa Lancaster8Division of Allergy, Pulmonary and Critical Care Medicine, Vanderbilt University Medical Center, Nashville, TN,David Lederer9Department of Clinical Medicine, Columbia University Medical Center, New York, NY,Jonathan A. Leff3Research & Development, InterMune Inc., Brisbane, CA,Steven D. Nathan10Advanced Lung Disease & Transplant Program, Inova Fairfax Hospital, Falls Church, VA,Carlos A. Pereira11Department of Medicine, Paulista School of Medicine, São Paulo, BrazilJeffrey J. Swigris12Department of Medicine, National Jewish Health, Denver, CO,Dominique Valeyre13Service de Pneumologie, Assistance Publique-Hôpitaux de Paris, Hôpital Avicenne, Bobginy, FranceTalmadge E. King Jr14Department of Medicine, University of California, San Francisco School of Medicine, San Francisco, CA,
- Effect of pirfenidone on treatment-emergent (TE) all-cause mortality (ACM) in patients with idiopathic pulmonary fibrosis (IPF): Pooled data analysis from ASCEND and CAPACITYBy Steven D. Nathan, Carlo Albera, Williamson Z. Bradford, Ulrich Costabel, Roland M. du Bois, Elizabeth A. Fagan, Ian Glaspole, Marilyn K. Glassberg, David Kardatzke, Talmadge E. King, Klaus-Uwe Kirchgaessler, Lisa H. Lancaster, David J. Lederer, Carlos A. Pereira, Jeffrey J. Swigris, Dominique Valeyre and Paul W. NobleSteven D. Nathan1Lung Transplant Program, Inova Fairfax Hospital, Falls Church, VA United StatesCarlo Albera2Clinical and Biological Sciences, University of Turin, Turin, ItalyWilliamson Z. Bradford3Intermune, Brisbane, CA United StatesUlrich Costabel4Pneumology and Allergy, Ruhrlandklinik, Essen, GermanyRoland M. du Bois5Respiratory Medicine, Imperial College, London, United KingdomElizabeth A. Fagan3Intermune, Brisbane, CA United StatesIan Glaspole6Interstitial Lung Disease Unit, Alfred Hospital and Monash University, Melbourne, AustraliaMarilyn K. Glassberg7Medicine and Surgery, University of Miami Miller School of Medicine, Miami, FL United StatesDavid Kardatzke3Intermune, Brisbane, CA United StatesTalmadge E. King Jr.8Medicine, University of California - San Francisco, San Francisco, CA United StatesKlaus-Uwe Kirchgaessler9Roche, Basel, SwitzerlandLisa H. Lancaster10Medicine, Vanderbilt University Medical Center, Nahville, TN United StatesDavid J. Lederer11Lung Transplant Program, Columbia University, New York, United StatesCarlos A. Pereira12Paulista School of Medicine, Federal University of São Paulo, São Paulo, BrazilJeffrey J. Swigris13Medicine, National Jewish Health, Denver, CO United StatesDominique Valeyre14Assistance Publique-Hôpitaux de Paris, Avicenne University, Bobigny, FrancePaul W. Noble15Medicine, Cedars-Sinai Hospital, Los Angeles, CA United States
- Effect of baseline FVC on lung function decline with nintedanib in patients with IPFBy Toby M. Maher, Kevin R. Flaherty, Paul W. Noble, Carlo Vancheri, Wim A. Wuyts, Toshio Kimura, Christoph Hallmann, Susanne Stowasser and Luca RicheldiToby M. Maher1Royal Brompton and Harefield NHS Foundation Trust, and National Heart and Lung Institute, Imperial College, London, United KingdomKevin R. Flaherty2Department of Internal Medicine, University of Michigan Health System, Ann Arbor, MI United StatesPaul W. Noble3Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA United StatesCarlo Vancheri4Department of Clinical and Experimental Medicine, University of Catania, Catania, ItalyWim A. Wuyts5Department of Respiratory Medicine, University Hospitals Leuven, Leuven, BelgiumToshio Kimura6Biometrics & Data Management, Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim am Rhein, GermanyChristoph Hallmann7Respiratory Diseases, Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim am Rhein, GermanySusanne Stowasser7Respiratory Diseases, Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim am Rhein, GermanyLuca Richeldi8National Institute for Health Research Southampton Respiratory Biomedical Research Unit and Clinical and Experimental Sciences, University of Southampton, Southampton, United Kingdom
- Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trialsBy Paul W. Noble, Carlo Albera, Williamson Z. Bradford, Ulrich Costabel, Roland M. du Bois, Elizabeth A. Fagan, Robert S. Fishman, Ian Glaspole, Marilyn K. Glassberg, Lisa Lancaster, David J. Lederer, Jonathan A. Leff, Steven D. Nathan, Carlos A. Pereira, Jeffrey J. Swigris, Dominique Valeyre and Talmadge E. KingArticle | Published in 2015 in European Respiratory JournalPaul W. Noble1Cedars-Sinai Medical Center, Los Angeles, CA, USACarlo Albera2University of Turin, Turin, ItalyWilliamson Z. Bradford3InterMune Inc., Brisbane, CA, USAUlrich Costabel4Ruhrlandklinik, University of Duisburg-Essen, Essen, GermanyRoland M. du Bois5Imperial College, London, UKElizabeth A. Fagan3InterMune Inc., Brisbane, CA, USARobert S. Fishman3InterMune Inc., Brisbane, CA, USAIan Glaspole6Alfred Hospital and Monash University, Melbourne, AustraliaMarilyn K. Glassberg7University of Miami Miller School of Medicine, Miami, FL, USALisa Lancaster8Vanderbilt University Medical Center, Nashville, TN, USADavid J. Lederer9Columbia University Medical Center, New York, NY, USAJonathan A. Leff3InterMune Inc., Brisbane, CA, USASteven D. Nathan10Inova Fairfax Hospital, Falls Church, VA, USACarlos A. Pereira11Paulista School of Medicine, Federal University of São Paulo, São Paulo, BrazilJeffrey J. Swigris12National Jewish Health, Denver, CO, USADominique Valeyre13Assistance Publique-Hôpitaux de Paris, Avicenne University Hospital, Bobigny, FranceTalmadge E. King Jr14University of California, San Francisco, San Francisco, CA, USA
- Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trialsBy Paul W. Noble, Carlo Albera, Williamson Z. Bradford, Ulrich Costabel, Roland M. du Bois, Elizabeth A. Fagan, Robert S. Fishman, Ian Glaspole, Marilyn K. Glassberg, Lisa Lancaster, David J. Lederer, Jonathan A. Leff, Steven D. Nathan, Carlos A. Pereira, Jeffrey J. Swigris, Dominique Valeyre and Talmadge E. KingPaul W. Noble1Cedars-Sinai Medical Center, Los Angeles, CA, USACarlo Albera2University of Turin, Turin, ItalyWilliamson Z. Bradford3InterMune Inc., Brisbane, CA, USAUlrich Costabel4Ruhrlandklinik, University of Duisburg-Essen, Essen, GermanyRoland M. du Bois5Imperial College, London, UKElizabeth A. Fagan3InterMune Inc., Brisbane, CA, USARobert S. Fishman3InterMune Inc., Brisbane, CA, USAIan Glaspole6Alfred Hospital and Monash University, Melbourne, AustraliaMarilyn K. Glassberg7University of Miami Miller School of Medicine, Miami, FL, USALisa Lancaster8Vanderbilt University Medical Center, Nashville, TN, USADavid J. Lederer9Columbia University Medical Center, New York, NY, USAJonathan A. Leff3InterMune Inc., Brisbane, CA, USASteven D. Nathan10Inova Fairfax Hospital, Falls Church, VA, USACarlos A. Pereira11Paulista School of Medicine, Federal University of São Paulo, São Paulo, BrazilJeffrey J. Swigris12National Jewish Health, Denver, CO, USADominique Valeyre13Assistance Publique-Hôpitaux de Paris, Avicenne University Hospital, Bobigny, FranceTalmadge E. King Jr14University of California, San Francisco, San Francisco, CA, USA
Buying books on this site
Purchases made on this website are of electronic books only.
About the ERS books
The ERS Monograph is the quarterly book series from the European Respiratory Society. Each Monograph covers a specific area of respiratory medicine, providing in-depth reviews that give clinicians at all levels a concise, comprehensive guide to symptoms, diagnosis and treatment.
The ERS Handbooks are compact guides to broad areas of the respiratory field. Launched in 2010, the series now covers adult, paediatric and sleep respiratory medicine, includes a companion volume of self-assessment questions and features the ERS Practical Handbooks.